Trials / Conditions / Severe Hepatic Impairment

Severe Hepatic Impairment

9 registered clinical trials studyying Severe Hepatic Impairment — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants NCT07250633	Institut de Recherches Internationales Servier (I.R.I.S.)	Phase 1
Completed	A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction NCT05224609	Pfizer	Phase 1
Completed	An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143 NCT05199610	EQRx International, Inc.	Phase 1
Completed	Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients NCT05116826	Genfit	Phase 1
Completed	Evaluate Severe Hepatic Impairment on Dacomitinib PK NCT03865446	Pfizer	Phase 1
Terminated	Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects NCT03818672	Bausch Health Americas, Inc.	Phase 4
Completed	PK Study in Subjects With Severe Hepatic Impairment NCT03664544	Tanabe Pharma Corporation	Phase 1
Completed	Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairm NCT02170220	Takeda	Phase 1
Completed	A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerab NCT02138162	Astellas Pharma Europe B.V.	Phase 1